UNASSIGNED: The retrospective study included 68 psoriatic arthritis patients followed up between October 2018 and October 2021. The patients were divided into two groups according to their anti-TNF-α treatment history. Group 1 consisted of 29 patients (11 males, 18 females; mean age: 45.3±13.3 years; range, 21 to 69 years) who had previously received one anti-TNF-α agent, while Group 2 included 39 patients (18 males, 21 females; mean age: 46.4±13.0 years; range, 24 to 70 years) who had been treated with two or more anti-TNF-α agents. Treatment responses of the groups were measured and compared using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Visual Analog Scale (VAS). A posttreatment BASDAI score ≤4 was used as a criterion for remission.
UNASSIGNED: The mean duration of secukinumab treatment was 16.6±12.7 months for Group 1 and 16.0±11.6 months for Group 2 (p=0.84). Both groups responded significantly to secukinumab in terms of BASDAI and VAS scores (p<0.001 and p<0.001, respectively). Group 1 had a greater decline in BASDAI and VAS scores than Group 2 (p=0.045 and p=0.032, respectively). Furthermore, the remission rate was greater in Group 1 compared to Group 2 (58% vs. 34%, p=0.03). The adverse effects of secukinumab treatment were an allergic reaction in Group 1 and one case of ulcerative colitis in Group 2.
UNASSIGNED: Second-line secukinumab treatment resulted in a greater decline in BASDAI and VAS scores. Moreover, secukinumab achieved a significantly higher rate of remission when it was used as second-line therapy after one anti-TNF-α agent.
■回顾性研究包括2018年10月至2021年10月随访的68例银屑病关节炎患者。根据患者抗TNF-α治疗史分为两组。第1组包括29名患者(11名男性,18名女性;平均年龄:45.3±13.3岁;范围,21至69岁)之前曾接受过一种抗TNF-α药物,而第二组包括39名患者(18名男性,21名女性;平均年龄:46.4±13.0岁;范围,24至70岁),曾接受过两种或多种抗TNF-α药物治疗。使用Bath强直性脊柱炎疾病活动指数(BASDAI)和视觉模拟量表(VAS)测量并比较两组的治疗反应。治疗后BASDAI评分≤4被用作缓解的标准。
■苏金单抗治疗的平均持续时间1组为16.6±12.7个月,2组为16.0±11.6个月(p=0.84)。两组在BASDAI和VAS评分方面对苏金单抗均有显著反应(分别为p<0.001和p<0.001)。与第2组相比,第1组的BASDAI和VAS评分下降幅度更大(分别为p=0.045和p=0.032)。此外,与第2组相比,第1组的缓解率更高(58%vs.34%,p=0.03)。苏金单抗治疗的不良反应为第1组的过敏反应和第2组的1例溃疡性结肠炎。
■二线苏金单抗治疗导致BASDAI和VAS评分下降幅度更大。此外,苏金单抗作为一种抗TNF-α药物后的二线治疗方案,其缓解率显著较高.